Lupin Employee Stock Options

Business Update

Lupin Business Update

Lupin Limited disclosed that the U.S. FDA concluded an inspection at its Goa manufacturing facility, closing with a Form-483 containing one observation. The company will respond within the stipulated timeframe.

Management Change

Lupin Management Change

Lupin Limited appointed Mr. Brian Savage as President and Chief Legal Officer, effective October 22, 2026. He will oversee global legal, compliance, and IP functions.

Board Meeting Date

Lupin Board Meeting Date

Lupin Limited scheduled a Board meeting on November 03, 2026, to consider and approve its unaudited standalone and consolidated financial results.

Other Announcement

Lupin Other Announcement

Lupin Limited received an ESG rating of 70 for FY26 from NSE Sustainability Ratings and Analytics. The assessment was independently prepared using publicly available information.

Regulatory ApprovalAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Lupin Regulatory Approval

Lupin Limited received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion, USP (1 mg/0.5 mL single-dose prefilled syringe).

Product LaunchAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Lupin Product Launch

Lupin Limited launched Formoflo-G® MDI, the world's first fixed-dose triple combination inhaler for COPD management in India. This follows approval from the Drug Controller General of India.

Employee Stock OptionsAye Finance Ltd AYE

Aye Finance Employee Stock Options

Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.

Employee Stock OptionsAarti Pharmalabs Ltd AARTIPHARM

Aarti Pharmalabs Employee Stock Options

Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.

Employee Stock OptionsOnEMI Technology Solutions Ltd KISSHT

OnEMI Technology Solutions Employee Stock Options

OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.

Employee Stock OptionsBliss GVS Pharma Ltd BLISSGVS

Bliss GVS Pharma Employee Stock Options

Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.

Employee Stock OptionsBandhan Bank Ltd BANDHANBNK

Bandhan Bank Employee Stock Options

Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.

Employee Stock OptionsMaxvolt Energy Industries Ltd MAXVOLT

Maxvolt Energy Industries Employee Stock Options

Maxvolt Energy granted 5,01,726 ESOPs to six employees under its MEIL ESOP 2025 scheme at exercise prices of ₹30 and ₹45. Options vest over four years, with exercise windows following vesting.

Execution

Vesting over 4 years from grant (25% at 2nd, 25% at 3rd, 50% at 4th anniversary); exercise over 3 years from each vesting date